glp-1 and beta blockers Bridging the gap between GLP1-receptor agonists cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology A Closer Look at the

The coverage pullback reflected an industry-wide reassessment of GLP-1 weight loss drug benefits

Corresponding numbers needed to harm were 3333 and 2778, respectively

DPP-4 Inhibitors Mechanism of action Competitive inhibition of dipeptidyl-peptidase 4 slows degradation of endogenous incretins (GLP-1, GIP) Glucose-dependent insulin secretion Post-prandial glucagon release No direct effect on weight or insulin sensitivity Glycaemic efficacy Advantages Weight-neutral useful when metformin + SU cause weight concern Low hypoglycaemia risk (incretin-dependent action) Oral, generally once-daily

This property was demonstrated in studies by Sikiric et al

K.AgarwalS.TripathiA.ChaturvediR

previously called nonalcoholic steatohepatitis [NASH]